Dermata Therapeutics (DRMA) Q3 2025 earnings summary

Executive summary

• Announced positive Phase 3 results for XYNGARI™ in March 2025, meeting all co-primary endpoints for moderate-to-severe acne, and in September 2025 shifted strategy to focus on developing and commercializing OTC dermatology products leveraging Spongilla technology.

• Strategic pivot aims to accelerate commercialization, reduce regulatory burden, and address broader consumer segments, with first OTC product launch targeted for mid-2026.

• Plans to launch a once-weekly acne kit in mid-2026, targeting consumers, estheticians, and dermatologists.

• No product revenue generated to date; operations funded primarily through equity and debt financings.

Financial highlights

• Net loss for the three months ended September 30, 2025 was $1.7 million, an improvement from $3.2 million in the same quarter last year; net loss per share was $(1.65) compared to $(20.41) in Q3 2024.

• Net loss for the nine months ended September 30, 2025 was $5.7 million, compared to $9.1 million for the same period in 2024.

• Cash and cash equivalents totaled $4.7 million as of September 30, 2025, up from $3.2 million at December 31, 2024, with an accumulated deficit of $71.4 million.

• Cash used in operations for the nine months ended September 30, 2025 was $6.4 million; cash provided by financing activities was $7.9 million.

• Research and development expenses for Q3 2025 were $0.5 million, down from $2.4 million in Q3 2024, mainly due to reduced clinical expenses after STAR-1 study completion.

Outlook and guidance

• Cash resources expected to fund operations into the second quarter of 2026; additional capital will be needed to sustain operations and support the OTC product launch.

• First OTC acne kit launch planned for mid-2026, with ongoing development of additional OTC products.

• Anticipates continued net losses until product revenues exceed operating expenses.